Human medicines European public assessment report (EPAR): Solymbic, adalimumab, Arthritis, Psoriatic,Spondylitis, Ankylosing,Crohn Disease,Colitis, Ulcerative,Hidradenitis Suppurativa,Psoriasis,Arthritis, Rheumatoid, Date of authorisation: 22/03/2017, Revision: 2, Status: Withdrawn